Clinical Application


ALL Panel

Detection of BCR-ABL, E2A-PBX1, MLL-AF4 and TEL-AML1

Real-Time Quantitative PCR

E2A-PBX1 t(1;19)

Minimal residual disease (MRD) detection of t (1; 19) for ALL.

Real-Time Quantitative PCR

MLL-AF4 t(4;11)

MRD detection of t (4; 11) and prognostic indicator for ALL.

Real-Time Quantitative PCR

TEL-AML1 t(12;21)

MRD detection of t (12; 21) and prognostic indicator for ALL.

Real-Time Quantitative PCR

BCR-ABL t(9;22)

Detection and quantitative monitoring of t (9; 22) for CML and ALL.

Real-Time Quantitative PCR

AML Panel

Detection of PML-RARA, AML1-ETO and CBFB-MYH11

Real-Time Quantitative PCR

PML-RARA t(15;17)

Detection and quantitative monitoring of t (15; 17) for APL. STAT same day analysis available for diagnostic specimens.

Real-Time Quantitative PCR

AML 1-ETO t(8;21)

Detection and monitoring of t (8; 21). Favorable prognosis in AML.

Real-Time Quantitative PCR

CBFB-MYH11 inv(16)

Detection and monitoring of inv (16). Favorable prognosis in AML.

Real-Time Quantitative PCR


Detection and monitoring of del (4q12) in HES (hypereosinophilic syndrome) and CEL (chronic eosinophilic leukemia).

Real-Time Quantitative PCR


V617F JAK2 (Janus kinas 2) point mutation detection for diagnosis of myeloproliferative disorders. High detection sensitivity (0.1 %). Heterozygous versus Homozygous profile detection.

Point Mutation Assay


Certain mutations in the KRAS gene prevent the therapeutic success of therapies that can cause this kind of activation that renders anti-EGFR therapies ineffective.

Point Mutation Assay


BRAF encodes a serine/threonine protein kinase which plays a role in signaling pathways involved in cell proliferation and differentiation.Some BRAF mutations significantly increase the BRAF gene product leading to neoplastic growth. Identification of BRAF genetic variants is thus the key to the best therapy for melanoma and thyroid cancer.

Point Mutation Assay



Target Mutation assay



Full Sequencing


5-Fluorouracil (5-FU) is widely and successfully used for the treatment of solid tumors. In some patients, however, an enzyme variant results in the need of therapy adjustment. The PGX-5FU test identifies the most common mutation with therapeutic relevance for 5-FU treatment.


Alpha 1-antitripsine


Target Mutation assay


مركز تحقيقات هماتولوژی
دانشگاه علوم پزشكی شيراز
نشانی: شیراز - خیابان خلیلی-برج تحقیقات محمد رسول الله-طبقه ششم-مرکز تحقیقات هماتولوژی 
تلفن های تماس: 07136122263-07136281528
فاکس: 07136281563
پست الکترونیک: